Skip to main content
. 2022 Feb 14;17(2):e0263822. doi: 10.1371/journal.pone.0263822

Fig 4. Analysis of tumor vascularity of DIPGXIIIp* and DIPGIV CAM tumors following drug treatment.

Fig 4

DIPGXIIIp* (A) and DIPGIV (B) CAM tumors were treated with alisertib, bortezomib, MSN1-Leu, panobinostat, ponatinib and bevacizumab on embryonic development days 11, 13 and 15. Tumor vascularity was assessed following 3-D ultrasound on embryonic development day 16. Vehicle is 0.5% DMSO in sterile PBS. PBS control is 100% sterile PBS. Differences were determined with one-way ANOVA and Dunnett’s test for multiple comparisons where P<0.05 is considered significant. P<0.05 = *, P<0.01 = **, P<0.001 = ***, P<0.0001 = ****.